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Experimental Section 
Preparation of 1-4 and 7 
1-4 and 7 were obtained as previously reported.[1, 2] 
 
Preparation of 5 
The compound was purchased from Ryan Scientific (Mt. Pleasant, SC) and was 
purified by column chromatography (Al2O3, 3:1 hexanes : ethyl acetate (EtOAc), 
Rf = 0.51). Yellow oil. 1H NMR [400 MHz; (CD3)2SO] d (ppm): 8.51 (1H, dd, J = 4 
Hz), 7.72 (1H, t, J = 8 Hz), 7.37 (1H, dd, J = 8 Hz), 7.23 (1H, t, J = 8 Hz), 6.54 
(4H, q, J = 12 Hz), 5.67 (1H, t, J = 8 Hz), 4.28 (2H, d, J = 4 Hz), 3.10 (4H, q, J = 8 
Hz), 0.96 (6H, t, J = 8 Hz). 13C NMR (100 MHz; (CD3)2SO) d (ppm): 160.3, 148.7, 
140.5, 139.8, 136.5, 121.8, 121.1, 116.5, 113.6, 49.47, 44.81, 12.37. HRMS 
Calcd for C16H22N3 [M+H]+: 256.1814; found 256.1808. 
 
Preparation of 6 
The compound was purchased from Ryan Scientific, dried under vacuum to 
remove all traces of solvents, and used without any further purification (tan 
powder). 1H NMR [400 MHz, (CD3)2SO] d (ppm): 8.51 (d, 1H, J = 4 Hz), 7.71 (t, 
1H, J = 8 Hz), 7.21 (d, 1H, J = 8 Hz), 7.24 (d, 1H, J = 8 Hz), 6.73 (d, 2H, J = 8 
Hz), 6.51 (d, 2H, J = 8 Hz), 5.93 (t, 1H, J = 8 Hz), 4.29 (d, 2H, J = 4 Hz), 3.68 (t, 
4H, J = 4 Hz), 2.86 (t, 4H, J = 4 Hz). 13C NMR (100 MHz, CD2Cl2) d (ppm): 159.2, 
149.5, 144.1, 142.8, 136.7, 122.3, 121.89, 118.4, 114.2, 67.39, 51.5, 50.2. HRMS 
(m/z): [M+H]+ Calcd for C16H20N3O, 270.1601; found, 270.1595. 
 
Preparation of 8 
The compound was purchased from Ryan Scientific and was recrystallized from 
1:1 CH2Cl2 : hexanes 1x and washed 2x with hexanes. Light brown powder. 1H 
NMR (400 MHz; CD2Cl2) d (ppm): 8.55 (d, 1H, J = 4 Hz), 7.61 (t, 1H, J = 8 Hz), 
7.33 (d, 1H, J = 4 Hz), 6.63 (d, 2H, J = 8 Hz), 6.53 (d, 2H, J = 8 Hz), 4.52 (m, 1H), 
4.15 (s, 1H), 2.76 (s, 6H), 1.49 (d, 3H, J = 4 Hz). 13C NMR (100 MHz, CD2Cl2) d 
(ppm): 165.1, 149.7, 144.7, 140.1, 137.0, 122.3, 120.9, 115.8, 115.4, 56.0, 42.3, 
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23.6. HRMS Calcd for C15H20N3 [M+H]+: 242.1652; found 242.1649. 
 
Preparation of 9 
The compound was purchased from Ryan Scientific (Mt. Pleasant, SC) and was 
recrystallized from EtOAc, CH2Cl2/hexanes, and washed twice with hexanes or 
dissolved in EtOAc and filtered over a neutral aluminum oxide plug. 1H NMR [400 
MHz, (CD3)2SO] d (ppm): 7.04 (d, 1H, J = 4 Hz), 6.76 (d, 1H, J = 4 Hz), 6.63 (m, 
4H), 5.36 (t, 1H, J = 4 Hz), 4.18 (d, 2H, J = 4 Hz), 3.62 (s, 3H), 2.70 (s, 6H). 13C 
NMR (100 MHz; CD2Cl2) d (ppm): 146.2, 145.2, 140.7, 127.5, 121.9, 115.8, 
151.2, 42.5, 42.3, 30.0. HRMS Calcd for C13H19N4 [M+H]+: 231.1604; found 
231.1603. 
 
Calculation of ionization potentials 
First-principles calculations using Gaussian09[3] were performed using previously 
reported procedures.[1] Oxidation potentials were calculated using only 
thermodynamic parameters due to the difficulty of computing the kinetics of 
electron transfer steps. All the relevant chemical species were optimized at 
M06/6-31G(d) level, and their thermodynamic parameters were calculated at 
M06/6-311+G(2df,2p) level. All compounds were assumed to oxidize through the 
same pathway.  
 
Electrochemistry 
Cyclic voltammograms were recorded under N2 (g) with a CHI620E model 
potentiostat (Qrins, Seoul, Republic of Korea). A three-electrode setup was 
utilized, consisting of a Ag/AgNO3 reference electrode (Qrins, Seoul, Republic of 
Korea), a Pt wire auxiliary electrode (SPTE Platinum electrode; Qrins, Seoul, 
Republic of Korea), and a glassy carbon working electrode (Qrins, Seoul, 
Republic of Korea). The supporting electrolyte was 0.1 M (Bu4N)(ClO4) in DMSO. 
 
Parallel artificial membrane permeability assay adapted for blood-brain barrier 
(PAMPA-BBB) 
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PAMPA-BBB experiments were carried out using the PAMPA Explorer kit (pION 
Inc., Billerica, MA, USA) using previously reported protocols.[1, 2, 4] UV−Vis 
absorbance values of the solutions in the reference, acceptor, and donor plates 
were measured using a microplate reader. The PAMPA Explorer software v. 3.5 
(pION) was used to calculate the −logPe values for the compounds. CNS± 
designations were assigned by comparison to compounds that were identified in 
previous reports.[2, 5-7] 
 
Ab aggregation experiments 
Ab experiments were performed according to previously published methods.[1, 2, 4] 
Prior to experiments, Ab40 or Ab42 was dissolved in ammonium hydroxide 
(NH4OH; 1% v/v, aq). The resulting solution was aliquoted, lyophilized overnight, 
and stored at −80 °C. A stock solution of Ab was then prepared by dissolving 
lyophilized peptide in 1% NH4OH (10 µL) and diluting with ddH2O. The 
concentration of the solution was determined by measuring the absorbance of the 
solution at 280 nm (e = 1450 M–1cm–1 for Ab40; e = 1490 M–1cm–1 for Ab42). The 
peptide stock solution was diluted to a final concentration of 25 µM in Chelex-
treated buffered solution containing HEPES [20 µM, pH 6.6 (for CuII samples) or 
pH 7.4 (for metal-free and ZnII samples)] and NaCl (150 µM). For the inhibition 
studies, compounds (final concentration 50 µM, 1% v/v DMSO) were added to 
the sample of Ab (25 µM) in the absence and presence of a metal chloride salt 
(CuCl2 or ZnCl2; 25, 50, 100 or 250 µM) followed by incubation at 37 °C with 
constant agitation for 4 or 24 h. For the disaggregation studies, Ab with and 
without a metal chloride salt was incubated for 24 h at 37 °C with constant 
agitation to generate preformed Ab aggregates. The resulting samples were then 
treated with compounds (50 µM) and incubated with constant agitation for 
additional 4 or 24 h. 
 
Gel electrophoresis and Western blotting 
The samples from the inhibition and disaggregation experiments were analyzed 
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by gel electrophoresis followed by Western blotting using an anti-Ab antibody 
(6E10) using previously established procedures.[1, 2, 4] Samples (10 µL) were 
separated on a 10-20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA). 
Following separation, the proteins were transferred onto nitrocellulose 
membranes and blocked with bovine serum albumin (BSA, 3% w/v, Sigma-
Aldrich, St. Louis, MO, USA) in Tris-buffered saline (TBS) containing 0.1% 
Tween-20 (TBS-T) for 2 h at room temperature or overnight at 4 °C. The 
membranes were incubated with an anti-Ab antibody (6E10, 1:2,000, Covance, 
Princeton, NJ, USA) in a solution of 2% BSA (w/v in TBS-T) for 4 h at room 
temperature or overnight at 4 °C. After washing with TBS-T (3x, 10 min), a 
horseradish peroxidase-conjugated goat antimouse secondary antibody (1:5,000 
in 2% BSA w/v in TBS-T; Cayman Chemical Company, Ann Arbor, MI, USA) was 
added for 1 h at room temperature. The Thermo Scientific SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA), Biosesang 
ECL Plus kit (Biosesang, Gyeonggi-do, Republic of Korea), or a homemade ECL 
kit[8] was used to visualize the results on a ChemiDoc MP Imaging System (Bio-
Rad, Hercules, CA, USA). 
 
Transmission electron microscopy (TEM) 
Samples for TEM were prepared according to a previously reported method using 
glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, 
Hatfield, PA, USA).[1, 2, 4] Images for each sample were taken on a JEOL JEM-
2100 transmission electron microscope [Ulsan National Institute of Science and 
Technology (UNIST) Central Research Facilities, UNIST, Ulsan, Republic of 
Korea]. 
 
Determination of solution speciation for the ZnII–1 Complex 
The acidity and stability constants values for ZnII–1 complex were determined by 
UV−Vis variable-pH titrations as previously reported.[2] A solution (100 mM NaCl, 
10 mM NaOH, pH 12) containing ZnCl2 and 1 (100 µM) in a metal to ligand ratio 
of 1:2 was titrated with small additions of HCl and at least 30 spectra were 
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recorded over the range pH 2−8. The acidity and stability constants were 
calculated by using the HypSpec program (Protonic Software, UK).[9] Speciation 
diagrams were modeled in the HySS2009 program (Protonic Software).[10] 
 
2D NMR spectroscopy 
The interaction of Ab40 with compounds were monitored by 2D band-Selective 
Optimized Flip-Angle Short Transient Heteronuclear Multiple Quantum 
Coherence (SOFAST-HMQC) at 8 °C.[11] Uniformly-15N-labeled Ab40 (rPeptide, 
Bogart, GA, USA) was first dissolved in 1% NH4OH and lyophilized. The peptide 
was re-dissolved in 3 µL of DMSO-d6 (Cambridge Isotope, Tewksbury, MA, USA) 
and diluted with phosphate buffer, NaCl, D2O, and ddH2O to a final peptide 
concentration of 80 µM (20 mM PO43-, pH 7.4, 50 mM NaCl, 7% v/v D2O). 
Ligands were dissolved in DMSO-d6 (50 mM) and titrated into the solution of 
Ab40. Each spectrum was obtained using 64 complex t1 points and a 0.1 sec 
recycle delay. The interaction of the tested compounds with ZnII–Ab40 was also 
explored by SOFAST-HMQC at 8 °C. Uniformly-15N-labeled Ab40 was treated as 
described above, but diluted into buffer containing 20 mM Tris, rather than PO43-, 
to avoid complex formation with the ZnII. To the solution of Ab40 was first added 1 
equiv ZnCl2 and then 1 equiv ligand was introduced to this solution. Each 
spectrum was obtained using 96 complex t1 points and a 0.1 sec recycle delay. 
All data were acquired on a Bruker Avance 600 MHz spectrometer equipped with 
a cryoprobe. The 2D data were processed using TOPSPIN 2.1 (Bruker). 
Resonance assignment was performed with SPARKY 3.1134 using published 
assignments for Ab40 as a guide.[12-14] Chemical shift perturbation (CSP) was 
calculated using the following equation: 
 
 
Ion mobility–mass spectrometry (IM–MS) 
All IM–MS experiments were carried out on a Synapt G2 (Waters, Milford, MA).[15, 
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16] Samples were ionized using a nano-electrospray ionization (nESI) source 
operated in positive ion mode. MS instrumentation was operated at a backing 
pressure of 2.7 mbar and sample cone voltage of 40 V. The m/z scale was 
calibrated using 20 mg/mL aqueous cesium iodide. For peptide-derivative-metal 
ligation studies aliquots of Ab40 peptides (final concentration 18 µM) were 
sonicated for 5 sec prior to preincubation with or without CuII (copper(II) acetate) 
at 37 °C for 10 min. After preincubation, samples were titrated with or without 5-9 
(20, 40, and 200 µM) and incubated in the absence of light at 37 °C for 30 min 
prior to analysis. Solution conditions were 100 mM ammonium acetate (pH 7.5) 
with 1% v/v DMSO. The m/z scale was calibrated using 20 mg/mL aqueous 
cesium iodide. Accurate mass values for covalently modified species were 
calculated using the monoisotopic peak difference between the apo and modified 
states. All other conditions are consistent with previously published methods.[1, 17] 
 
Antioxidant assay 
The antioxidant activity of the compounds was determined by the TEAC assay 
employing N2a cell line (ATCC, Manassas, VA, USA) lysates following the 
previous reported procedures.[1, 2, 4] The percent inhibition [% inhibition = 100 x 
(A0 – A)/A0] was calculated using the absorbance of the samples with compound 
(A) compared to the absorbance of control samples lacking compound (A0) and 
was plotted as a function of compound concentration. The TEAC value of ligands 
were calculated as a ratio of the slope of the standard curve of the compound to 
the slope of Trolox (Sigma-Aldrich; Trolox = 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid; dissolved in DMSO). Duplicate 
measurements were conducted in three different experiments. 
 
2-Deoxyribose assay 
The ability of compounds to control free radical formation from Fenton-like 
chemistry by CuI/II was determined using previously reported procedures.[1, 18, 19] 
 
Cell viability studies 
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The human neuroblastoma M17 cell line was purchased from the American Type 
Culture Collection (ATCC). The cell line was maintained in media containing 50% 
minimum essential medium (MEM) and 50% F12 (GIBCO, Grand Island, NY, 
USA), supplemented with 10% fetal bovine serum (FBS, Sigma), 100 U/mL 
penicillin, and 100 mg/mL streptomycin (GIBCO). The cells were grown and 
maintained at 37 °C in a humidified atmosphere with 5% CO2. Cell viability upon 
treatment of compounds was determined using the MTT assay (Sigma). M17 
cells were seeded in a 96 well plate (15,000 cells in 100 µL per well). The cells 
were treated with Ab (20 µM) with or without CuCl2 or ZnCl2 (20 µM), followed by 
the addition of compound (20 µM, 1% v/v final DMSO concentration) and 
incubated for 24 h with the cells. After incubation, 25 µL MTT (5 mg/mL in 
phosphate buffered saline (PBS, pH 7.4, GIBCO) was added to each well and the 
plate was incubated for 4 h at 37 °C. Formazan produced by the cells was 
solubilized using an acidic solution of N,N-dimethylformamide (DMF, 50%, v/v aq) 
and sodium dodecyl sulfate (SDS, 20%, w/v) overnight at room temperature in 
the dark. The absorbance was measured at 600 nm using a microplate reader. 
Cell viability was calculated relative to cells containing an equivalent amount of 
DMSO. 
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Table S1. Electrochemical parameters of 1-9. All compounds showed irreverisble 
waves with the exception of 7 which did not exhibit an observable electrochemical 
behavior. 
 
n (mV/s)a Epa1 (V)b Epa2 (V)c Epc1 (V)d ipa1 (µA)e ipa2 (µA)f Ipc1 (µA)g 
   Compound 1    
25 0.246 0.489 0.328 15.12 8.28 -8.78 
50 0.250 0.501 0.319 24.97 9.27 -11.12 
100 0.255 0.508 0.311 34.55 10.17 -13.91 
150 0.256 0.508 0.307 41.86 10.35 -17.91 
200 0.260 0.516 0.311 47.14 9.76 -17.63 
250 0.262 0.521 0.295 59.93 9.35 -22.11 
   Compound 2    
25 0.862 – – 53.59 – – 
50 0.878 – – 71.74 – – 
100 0.897 – – 93.80 – – 
150 0.903 – – 116.05 – – 
200 0.911 – – 134.45 – – 
250 0.923 – – 139.63 – – 
   Compound 3    
25 0.224 – – 36.22 – – 
50 0.242 – – 52.57 – – 
100 0.257 – – 70.64 – – 
150 0.271 – – 88.35 – – 
200 0.280 – – 98.62 – – 
250 0.284 – – 115.8 – – 
   Compound 4    
25 0.207 – – 37.1 – – 
50 0.221 – – 54.08 – – 
100 0.224 – – 88.45 – – 
150 0.240 – – 102.78 – – 
200 0.246 – – 123.67 – – 
250 0.240 – – 143.98 – – 
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   Compound 5    
25 0.175   31.70   
50 0.187   43.38   
100 0.203   59.57   
150 0.209   70.47   
200 0.212   80.40   
250 0.228   83.83   
   Compound 6    
25 0.327 – – 46.87 – – 
50 0.353 – – 69.48 – – 
100 0.374 – – 91.93 – – 
150 0.382 – – 111.20 – – 
200 0.398 – – 130.13 – – 
250 0.388 – – 153.04 – – 
   Compound 8    
25 0.245 – – 75.85 – – 
50 0.257 – – 105.26 – – 
100 0.272 – – 124.44 – – 
150 0.279 – – 150.26 – – 
200 0.284 – – 169.06 – – 
250 0.286 – – 186.9 – – 
   Compound 9    
25 0.213 – – 41.01 – – 
50 0.227 – – 61.15 – – 
100 0.241 – – 82.11 – – 
150 0.247 – – 99.11 – – 
200 0.249 – – 113.79 – – 
250 0.238 – – 142.15 – – 
 
a n, scan rate (mV/s); b Epa1, first peak anodic potential (V); c Epa2, second peak anoidic 
potential (V); d Epc1, first peak cathodic potential (V); e ipa1, first peak anodic current (µA); 
f ipa2, second peak anodic current (µA); g ipc1, first peak cathodic current (µA). 
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Table S2. Values (MW, clogP, HBA, HBD, PSA, logBB, and logPe) of 1-9. 
 
aMW, molecular weight; bclogP, calculated log of water-octanol partition coefficient; 
cHBA, hydrogen bond acceptor; dHBD, hydrogen bond donor; ePSA, polar surface area; 
flogBB = −0.0148 × PSA + 0.152 × clogP × 0.130; gDetermined using the Parallel 
Artificial Membrane Permeability Assay adapted for BBB (PAMPA-BBB). hCompounds 
categorized as CNS+ have the possibility to penetrate the BBB and are available in the 
CNS. Compounds assigned as CNS– have poor permeability through the BBB; 
therefore, their bioavailability into the CNS is considered to be minimal. 
 
  
Compound/ 
Parameters MW
a clogPb HBAc HBDd PSA (Å2)e logBBf −logPeg CNS +/- Predictionh Ref. 
1 199 1.96 3 3 50.9 −0.563 5.0(1) CNS+ 1 
2 244 1.73 4 1 43.4 −0.249 4.2(8) CNS+ 1 
3 277 3.14 3 1 28.2 0.191 4.2(2) CNS+ 1 
4 215 1.86 3 2 31.1 −0.047 4.9(0) CNS+ 1 
5 255 2.82 3 1 28.2 0.141 4.4(2) CNS+ this work 
6 269 1.05 4 1 37.9 −0.272 4.6(5) CNS+ this work 
7 229 1.98 5 3 4 −0.696 4.2(1) CNS+ this work 
8 241 2.07 1 1 1 0.0273 4.3(7) CNS+ this work 
9 230 1.10 76.2 28.2 33.1 −0.193 4.7(3) CNS+ this work 
Lipinski’s 
rules & 
Others 
≤ 450 ≤ 5.0 ≤ 10 ≤ 5 ≤ 90 
< −1.0 
poorly 
distributed 
in the brain 
−logPe < 5.4 (CNS+); 
−logPe > 5.7 (CNS-) 
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Figure S1. Cyclic voltametric analysis of 1. Plot of the current (ipa and ipc) as a function 
of the (scan rate)1/2 (i.e., n1/2), indicating the irreversible oxidation of 1. Conditions: [1] = 
1 mM; scan rate = 25, 50, 100, 150, 200, and 250 mV/s; room temperature; supporting 
electrolyte, 0.1 M (Bu4N)(ClO4) in DMSO.  
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Figure S2. Inhibition of Ab40 aggregation by 1-9. Analysis of the molecular weight of the 
resultant Ab species after (a) 24 h or (b) 4 h treatment in the absence (left) or presence 
of CuII (middle; blue) or ZnII (right; green) by gel electrophoresis and subsequent 
Western blotting (gel/Western blot) with an anti-Ab antibody (6E10). (c) Morphologies of 
metal-free Ab (left), CuII-Ab (center), and ZnII-Ab (right) after 24 h incubation with the 
compounds, observed by TEM. Conditions: [Ab] = 25 µM; [CuII or ZnII] = 25 µM; 
[compound] = 50 µM; pH 6.6 (for CuII-containing samples) or pH 7.4 (for metal-free and 
ZnII-containing samples); 37 oC; constant agitation. 
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Figure S3. Disaggregation of preformed Ab42 aggregates by 1-9. (a) Scheme of the 
disaggregation experiments. Mixtures of freshly prepared Ab with or without CuII (blue) 
or ZnII (green) were treated with compounds (1-9) and incubated for 4 h or 24 h before 
analysis. Samples excluding compounds (lane C) were also prepared as a control. 
Conditions: [Ab] = 25 µM; [MII] = 25 µM; [compound] = 50 µM; pH 6.6 (for CuII-
containing samples) or pH 7.4 (for metal-free and ZnII-containing samples); 37 oC; 
constant agitation. (b) Analysis of the molecular weight of the resultant Ab species after 
4 h or 24 h incubation in the absence (left) or presence of CuII (middle) or ZnII (right) by 
gel electrophoresis and subsequent Western blotting (gel/Western blot) with an anti-
Ab antibody (6E10). (c) TEM images of the Ab aggregates before (top) and after 
treatment with 5 and 6 (bottom) (scale bar = 200 nm).   
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Figure S4. Disaggregation of preformed Ab40 aggregates by 1-9. Analysis of the 
molecular weight of the resultant Ab species after (a) 24 h or (b) 4 h treatment in the 
absence (left) or presence of CuII (middle; blue) or ZnII (right; green) by gel 
electrophoresis and subsequent Western blotting (gel/Western blot) with an anti-
Ab antibody (6E10). (c) Morphologies of metal-free Ab (left), CuII-Ab (center), and 
ZnII-Ab (right) after 24 h incubation with the compounds, visualized by TEM. Conditions: 
[Ab] = 25 µM; [CuII or ZnII] = 25 µM; [compound] = 50 µM; pH 6.6 (for CuII-containing 
samples) or pH 7.4 (for metal-free and ZnII-added samples); 37 oC; constant agitation. 
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Figure S5. Inhibitory activity of compounds on Ab40 aggregation at higher ratios of metal 
to compound under the conditions of the inhibition experiments (Figure 2a) employing 1 
equiv (left; 50 µM), 2 equiv (middle; 100 µM), and 5 equiv (right; 250 µM) of (a) CuII and 
(b) ZnII. 
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Figure S6. Interactions of compounds with 15N-labeled Ab40. SOFAST-HMQC NMR 
(600 MHz) spectra before (blue) and after (red) addition of 10 equiv of (a) 1, (b) 2, (c) 3, 
(d) 4, (e) 5, (f) 6, (g) 7, (h) 8, and (i) 9. Conditions: [15N-labeled Ab40] = 80 µM; 
[compound] = 800 µM; 20 mM PO43-, pH 7.4, 50 mM NaCl, 7% v/v D2O; 8 °C. 
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Figure S7. Mass spectrometric analysis of Ab40 incubated with 5-9 in the absence of a 
source of CuII. In the absence of CuII, no evidence of interactions between small 
molecules and metal-free Ab was observed with all data consistent with compound-free 
controls. Conditions: [Ab40] = 20 µM (3+ charge state shown); [compound] = 200 µM. 
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Figure S8. Solution speciation studies of the ZnII-1 complex. (a) Variable pH UV-Vis 
titration spectra for ZnII-1 to determine stability constants (c, logb) of ZnII-L species and 
generate speciation diagrams (b, FZn = Fraction of free ZnII and ZnII-L). Parenthesis 
indicates that the error is in the last digit of the values. Conditions: ZnII:L = 1:2; [1] = 100 
µM; samples were incubated at room temperature for 24 h before titrations. Charges 
omitted for clarity. 
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Figure S9. SOFAST-HMQC NMR (900 MHz) spectra of 15N-labeled Ab40 before (red) 
and after addition of ZnII (blue) for the experiments with (left) 1, (middle) 4, and (right) 5. 
Conditions: [15N-labeled Ab40] = 80 µM; [ZnCl2] = 80 µM; [compound] = 80 µM; 20 mM 
PO43-, pH 7.4, 50 mM NaCl, 7% v/v D2O; 8 °C. 
 
